Ftse Mib
34.641,10
1,24%
DAX
18.407,07
1,33%
S&P 500
5.566,40
1,12%
NASDAQ
18.003,56
1,56%
Bitcoin
67.427,80
-1,07%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada CSE Defence Therapeutics Inc (DTC) Defence Therapeutics Inc (DTC) Notizie

DTC

Defence Therapeutics (DTC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:CSE:DTC
DataOraFonteTitoloSimboloCompagnia
16/02/202216:00InvestorsHub NewsWireDEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCERCSE:DTCDefence Therapeutics Inc
26/01/202214:49InvestorsHub NewsWireDefence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9CSE:DTCDefence Therapeutics Inc
30/11/202118:32InvestorsHub NewsWireDEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENTCSE:DTCDefence Therapeutics Inc
23/11/202114:24InvestorsHub NewsWireDEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCERCSE:DTCDefence Therapeutics Inc
09/11/202117:50InvestorsHub NewsWireDEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORSCSE:DTCDefence Therapeutics Inc
03/11/202113:11InvestorsHub NewsWireVACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITSCSE:DTCDefence Therapeutics Inc
13/10/202115:15InvestorsHub NewsWireDEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCERCSE:DTCDefence Therapeutics Inc
06/10/202115:32InvestorsHub NewsWireDEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMACSE:DTCDefence Therapeutics Inc
29/09/202114:30InvestorsHub NewsWireDEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCERCSE:DTCDefence Therapeutics Inc
20/09/202116:01InvestorsHub NewsWireDEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALSCSE:DTCDefence Therapeutics Inc
14/09/202114:13InvestorsHub NewsWireDEFENCE THERAPEUTICS SUCCESS IN TESTING IT'S COVID-19 ACCUVAC-PT001 VACCINE IN A NON-RODENT MODELCSE:DTCDefence Therapeutics Inc
07/09/202113:35InvestorsHub NewsWireDEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE INITIATEDCSE:DTCDefence Therapeutics Inc
01/09/202116:39InvestorsHub NewsWireThe vaccination specialist is about to become popularCSE:DTCDefence Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:CSE:DTC

La tua Cronologia

TG
3MX
Interra Copper
NASDAQ
ZALUZX
Converge Fund Iii
EU
PTVAACOM0009
Vaa Vista Alergre Atlant...
EU
FR001400OW18
SG Issuer Sg Issuer Mc M...
USOTC
ELIQQ
Electriq Power (CE)
TG
JP40
Amundi Jpxnikkei 400 Uci...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network